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Background: Neurological impairment is a common sequelae of perinatal brain injury. Plasticity of the developing brain is
due to a rich substrate of developing neurones, synaptic elements and extracellular matrix. Interventions supporting this
inherent capacity for plasticity may improve the developmental outcome of infants following brain injury. Nutritional
supplementation with combination docosahexaenoic acid, uridine and choline has been shown to increase synaptic
elements, dendritic density and neurotransmitter release in rodents, improving performance on cognitive tests. It remains
elusive whether such specific ‘neurotrophic’ supplementation enhances brain plasticity and repair after perinatal brain injury.
Methods/Design: This is a two year double-blind, randomised placebo controlled study with two cohorts to investigate
whether nutritional intervention with a neurotrophic dietary supplement improves growth and neurodevelopmental
outcomes in neonates at significant risk of neurological impairment (the D1 cohort), and infants with suspected or
confirmed cerebral palsy (the D2 cohort).
120 children will be randomised to receive dietetic and nutritional intervention, and either active supplement or
placebo. Eligible D1 neonates are those born <30+6 weeks gestation with weight <9th centile, ≤30+6 weeks gestation
and Grade II, III or IV Intra-Ventricular Haemorrhage or periventricular white matter injury, or those born at 31-40+28 weeks
gestation, with Sarnat grade I or II or III Hypoxic Ischaemic Encephalopathy or neuroimaging changes compatible with
perinatal brain injury. Eligible D2 infants are those aged 1-18 months with a suspected or confirmed clinical diagnosis of
cerebral palsy. The primary outcome measure is composite cognitive score on the Bayley Scales of Infant and Toddler
Development III at 24 months. Secondary outcomes include visuobehavioural and visual neurophysiological assessments,
and growth parameters including weight, height, and head circumference.
Discussion: This is the first study to supplement neonates and infants with perinatal brain injury with the combination
of factors required for healthy brain development, throughout the period of maximal brain growth. A further study
strength is the comprehensive range of outcome measures employed. If beneficial, supplementation with brain
phosphatide precursors could improve the quality of life of thousands of children with perinatal brain injury.
Trial registration: Current Controlled trials: ISRCTN39264076 (registration assigned 09/11/2012), ISRCTN15239951
(registration assigned 23/04/2010).
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Perinatal brain injury (PBI) has a range of consequences
dependent upon the exact timing, location and extent of
the brain insult. Brain white matter appears particularly
vulnerable to injury in the preterm period [1], whereas grey
matter injury is typically the consequence of acute injury
sustained around term [2]. It is now recognised, however,
that white and grey matter injury occur concurrently in
pre-term and term brain injury [3,4]. Cerebral palsy (CP) is
a common sequelae of brain injury in the antenatal, peri-
natal or postnatal period. CP describes “a group of per-
manent disorders of movement and posture, causing
activity limitation that is attributed to non-progressive dis-
turbances that occurred in the developing fetal or infant
brain. The motor disorders of CP are often accompanied
by disturbances of sensation, perception, cognition, com-
munication, and behaviour, by epilepsy, and by secondary
musculoskeletal problems” [5]. Although the brain injury
resulting in CP is non-progressive, its manifestations vary
throughout development. The incidence of CP worldwide
is between 2.0-2.5 per 1000 live births [6,7], and CP is
more common in infants born preterm, and in growth re-
stricted infants [7]. Perinatal brain injury does not inevit-
ably result in CP; however a range of cognitive and visual
impairments are common sequelae, even in those who do
not have severe motor impairment [8-10].
Brain plasticity and functional recovery
Brain plasticity describes a process whereby the brain is
functionally altered [11]. Studies of brain growth and de-
velopment suggest that, as a result of an abundance of
developing neurons and synaptic connections, the brain’s
capacity for plasticity is probably highest through mid-
gestation to early childhood [12]. It may also be true that
the substrate richness that underlies the developing
brain’s potential for plasticity also underlies its’ early vul-
nerability. Moreover, the outcome of perinatal brain in-
jury may depend on the precise timing of injury; insults
occurring during a “critical period” of development are
more likely to cause significant impairment [12,13]. By
contrast, insults occurring toward the end of specific de-
velopmental windows when critical neural connections
have been made are less likely to result in as severe im-
pairment [14].
The advent of more advanced neurophysiological and
neuroimaging techniques has provided direct evidence of
neuronal plasticity in infants and children [15]. For ex-
ample, in children with congenital hemiparesis developing
axons have been shown to re-route around areas of dam-
age to reach their intended cortical target [16]. Further-
more, in children with congenital hemiparesis intensive
therapy programmes can increase the size of primary hand
motor cortex motor contralateral to the paretic hand, with
associated functional improvement in the paretic hand[17-20]. Similar evidence for plasticity has also been dem-
onstrated in the visual system where diffusion tractography
imaging clearly identifies thalamo-cortical axon circum-
navigation of white matter damage, to reach their predeter-
mined destination in the occipital cortex [21].
Evidence supporting the plasticity potential of the de-
veloping brain raises the question of whether interven-
tions that support the regeneration of developing
neuronal projections might improve function as well as
structure, and reduce neurodisability.
Nutrition and brain development
The integrity and function of the brain depends in large
measure upon a specific profile of membrane lipids and
their fatty acids. In the brain, many enzymes involved in
neurotransmitter metabolism are lipid-dependant, as are
functions involved in the synthesis of brain structural
lipids. Phosphatidylcholine is the primary component of
neuronal cell membranes. The synthesis of brain phos-
phatidylcholine utilises three circulating precursors:
choline; a pyrimidine e.g. uridine-51-monophosphate
(UMP); and a polyunsaturated fatty acid (PUFA) e.g.
docosahexaenoic acid (DHA). Phosphatidylethanol-
amine, another component of neuronal cell membranes,
may utilise two of these precursors, a pyrimidine and a
PUFA. There is evidence in animals and humans that
dietary supplementation of the precursors of neuronal
cell membranes improves function. Dietary supplemen-
tation of rodents with a combination of DHA, choline
and UMP increases brain phosphatide levels [22], pre
and post-synaptic elements [22,23], and dendrite spine
density [24], and is associated with improved perform-
ance on cognitive tasks [25]. Dietary supplementation of
rats with UMP increase striatal levels of the neurotrans-
mitter acetylcholine, relevant to cognitive processes in
humans and other animals [26]. The first human rando-
mised placebo controlled trial of DHA, choline and
UMP has shown improvements in verbal recall on the
Weschler Memory Scale-revised in adults with early Alz-
heimer’s disease [27].
Nutrition and infant development
Infant milk formulae and normal feeding recommenda-
tions have been developed considering growth in weight
and length as the main outcomes. Recently there been
more consideration of neural development as an add-
itional outcome when determining the optimal nutrition
for neonates and infants.
Studies of improved early nutrition in preterm infants
have shown improved neurodevelopmental outcomes in
intervention groups [28,29]. Whether increased nutritional
intake in the first years of life in children with CP improves
growth or neurodevelopmental outcome, however, has not
been adequately studied. Recently, a small non randomized
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14 years showed that those who received 6 months of add-
itional nasogastric tube feeds, had improved growth and
gross motor functioning compared with a group who did
not receive supplements [30]. A further study identified in-
creased head circumference and corticospinal tract diam-
eter in infants fed with 120% of the recommended daily
allowance, however neurodevelopmental outcome data
was not reported [31].
The crucial role of long chain polyunsaturated fatty
acids (LCPUFA) in infant brain development has been
extensively investigated over the last decade. Studies
have provided inconclusive results of the potential neu-
rodevelopmental benefits of LCPUFA supplementation,
in preterm and term infants. This may be a result of
variation between conducted studies in design, maturity
of supplemented infants, supplementation dose and dur-
ation, and outcome measures used. A recent individual
patient data meta-analysis failed to show neurodevelop-
mental advantage of LCPUFA supplementation [32], but
did not include data from two relevant studies which
demonstrated improved performance on the Bayley
Scales of Infant Development (BSID) in pre-term [33]
and term infants [34]. The DINO study was the first trial
to supplement preterm infants with levels of DHA ap-
proaching maximal concentrations found in human
breast milk (around 1% total fatty acids) [35]. Infants
were supplemented until discharge from hospital. The
results of this randomised control trial (RCT) did not
show any difference in the incidence of CP, but did dem-
onstrate improved cognitive performance in preterm
girls (but not boys), and in infants with birth weight less
than 1250g in unadjusted analyses. Visual acuity was
also improved in cases at 4 months compared to con-
trols [35].
Whether or not the provision of adequate supplies of the
biochemical precursors of neuronal cell membranes such
as choline, uridine and DHA can improve neurological
function in brain damaged infants remains unknown and
has not been studied in infancy and childhood.Methods/Design
The overall aim of this study is to investigate whether
nutritional intervention providing adequate choline, uri-
dine and DHA supports the plasticity potential and re-
generation of neuronal projections in the developing
brain, to improve function and structure, and reduce
neurodisability.Primary objective
To investigate whether nutritional intervention, with sup-
plementation of choline, uridine and DHA improves neu-
rodevelopmental outcomes in neonates at significant riskof neurological impairment, and infants with suspected or
confirmed CP.
Secondary objectives
To investigate whether nutritional intervention improves
growth, visual outcomes and improved indices of general
health status, including prevalence of epilepsy, feeding
difficulties, clinically significant gastro-oesophageal re-
flux, constipation, chest infections (requiring antibiotics)
and hospital admissions.
Primary outcome measure
The primary outcome measure is performance on the
composite cognitive scale of the BSD- III following
24 months of supplementation.
Secondary outcome measures
 BSID-III composite cognitive scale at 12 months
 BSID-III composite language score at 12 and
24 months
 BSID-III composite motor score at 12 and
24 months
 Visual function, including Pattern Reversal Visual
Event Related Potential (PR-VERP) latency and
behavioural vision assessment score at 12 and
24 months
 Growth
◦ Weight for age z-score at 12 and 24 months
◦ Length for age z-score at 12 and 24 months
◦ Triceps skinfold thickness for age z-score at 12
and 24 months
◦ Mid-upper arm circumference for age z-score at
12 and 24 months
◦ Head circumference for age z-score at 12 and
24 monthsStudy design
The Dolphin studies are double-blind randomised
placebo-controlled trials of supplementation with a com-
bination of DHA, choline and uridine. Two cohorts will
be recruited:
Dolphin 1 (D1): Optimising nutrition to improve growth
and reduce neurodisabilities in neonates at risk of
neurological impairment and
Dolphin 2 (D2): Optimising nutrition to improve growth
and reduce neurodisabilities in children with suspected
or confirmed cerebral palsy.
Subject population
Term and pre-term neonates who are at significant risk of
neurological impairment, either as the result of a perinatal
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low birth weight (<9th centile).
Infants up to 18 months of age with a suspected or
confirmed diagnosis of CP, made by their consultant
paediatrician.
Neonatal inclusion criteria
Birth ≤30+6 weeks gestation and:
 Small for Gestational Age – weight less than 9th
centile OR
 Sarnat Grade IIa, IIb, III or IV Germinal Matrix
Haemorrhage (GMH) – Intra Ventricular
Haemorrhage (IVH) or pathological periventricular
flare/ leucomalacia
Birth 31-40+28 weeks gestation:
 Hypoxic Ischaemic Encephalopathy Sarnat Grade II
and III OR
 Grade IIa, IIb, III or IV GMH-IVH or pathological
periventricular flare/ leucomalacia OR
 Magnetic resonance imaging (MRI) abnormalities:
Posterior limb of the internal capsule (PLIC), basal
ganglia, thalami, white matter and cortex.
Consent to enter the trial will be obtained before the
infant is 4 weeks post term corrected age.
Infant inclusion criteria
Aged 1–18 months with a suspected or confirmed clin-
ical diagnosis of cerebral palsy according to their con-
sultant Paediatrician, using the following definition:
“A group of permanent disorders of the development of
movement and posture, causing activity limitations
that are attributed to non-progressive disturbances
that occurred in the developing fetal or infant brain.
The motor disorders of cerebral palsy are often
accompanied by disturbances of sensation, perception,
cognition, communication, and behaviour, by epilepsy,
and by secondary musculoskeletal problems” [5].
Exclusion criteria
◦ Progressive neurological conditions
◦ Gastrointestinal disease which significantly impairs
absorption
◦ Multiple congenital abnormalities or syndromic
associations
◦ Such low hearing that assessment with the Bayley
scales cannot be completed
◦ Parents considered by clinicians to be unable to follow
study protocolAnd for infants born at <36 weeks gestation:
◦ Grade I GMH-IVHIdentification and recruitment of participants
This is a multi-centre trial to be carried out at the
Oxford University Department of Paediatrics with 6 col-
laborating regional hospitals. Participants will be recruited
following referral from Neonatologists, Community Paedi-
atricians and Neurologists at these collaborating sites.Neonatal identification
Term and pre-term neonates will be recruited from the
neonatal units at the Oxford University Hospitals NHS
Trust, Oxford, the Royal Berkshire Hospital, Reading,
and Wexham Park Hospital, Slough. Eligible neonates
will be identified by the neonatal clinical team who make
the initial parental approach, with support from the re-
search team. The trial will only be discussed with the
parents when their baby is fully enterally fed and no lon-
ger receiving neonatal intensive care. With parental
agreement the research nurse (CMJ) or clinical research
fellow (MA) will then approach the family to discuss the
trial in more detail and give them the parent written
information.Infant identification
Paediatricians and Neurologists with knowledge of the in-
fant’s previous clinical history, presenting clinical condi-
tion, and study protocol will identify infants with a clinical
diagnosis of suspected or confirmed cerebral palsy at
the collaborating research sites. These sites are at Stoke
Mandeville Hospital and Wycombe General Hospitals
(Buckinghamshire Hospitals NHS Trust), Northampton
General Hospital (Northampton General Hospital NHS
Trust), Department of Child Health (Milton Keynes
Hospital NHS Foundation Trust), The Child Development
Centres at Upton Hospital, and St Marks Hospital,
(Heatherwood and Wexham Park Hospitals NHS Founda-
tion Trust), and the Dingley Specialist Children’s Centre at
the Royal Berkshire NHS Foundation Trust. With the lead
clinicians’ agreement, the clinical research fellow (MA) or
research nurse (CMJ) will contact the parents by telephone
to explain the trial in more detail and if they are interested,
send them written information.Consent procedures
Neonates
The research nurse or clinical research fellow will take
written consent, either on the neonatal unit or, if the
baby had been discharged subsequent to the written in-
formation being given, at the family home.
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Written consent will be taken by the research nurse or
clinical research fellow during a pre-arranged visit to the
family home.
Randomisation and blinding
Randomisation will be carried out by the study statistician
(NW) in the University of Oxford Centre for Statistics in
Medicine, Oxford (CSM). Randomisation will occur follow-
ing consent, at least 24 hours before start of supplementa-
tion. Both neonates and infants will be randomised to
intervention group X or Y, to receive dietetic and nutri-
tional intervention, with either active or placebo supple-
mentation. The randomisation programme will include a
minimisation algorithm which will be used to ensure bal-
anced distribution of children with different severities of
brain injury between intervention groups. The research
team will be notified by CSM of randomisation group by
return fax of the completed randomisation form.
Neonate stratification
Neonates will be allocated across the 2 treatment groups
by the following prognostic factors: gender, gestationalTable 1 Neuroimaging severity categorisation [2,49-57]
Normal/Mild
Preterm injury
• Cranial ultrasound scan
(cUSS)
• Normal
• Grade I/II Intraventricular haemorrhage
(IVH)
• Ventricular index (VI) < 13 mm Term
equivalent age (TEA) OR




• Magnetic resonance imaging
(MRI)
• Focal subtle abnormalities of BG
with normal appearance of the
posterior limb of the internal capsule (PLIC)
• cUSS where MRI unavailable • Periventricular white matter changes
difficult to differentiate from normal
appearances and therefore not
classified as abnormal
• Changes confined to cerebral cortex
and subcortical white matter (WM)
Term infarction
• MRI (cUSS where MRI
unavailable)age (≤30+6 weeks, ≥31 weeks) and severity of brain in-
jury (normal/mild, moderate, severe – see Table 1).
Infant stratification
Infants will be stratified by gender, age at recruitment
(1–5 months, 6–12 months, and 13–18 months), known
visual impairment at trial entry and severity of motor
disorder (4 limb involvement or other).
The research team will be blinded to treatment group
allocation with the exception of the trial dietician (KL)
and trial assistant (BB). KL will responsible for the deliv-
ery of supplement to participating families and will be
aware of group allocation (X or Y), as will be participat-
ing families. Unblinding at the end of the trial will be
undertaken by CSM.
Intervention
Parents will receive fortnightly input from the trial dietitian
(KL) to optimise macro- and micro-nutrient intake. Each
infant’s diet will be supplemented with 2g/kg/day of study
product for 2 years. The supplement will be added to the
infant’s milk or mixed with solids depending on the age
and diet of individual participants. Detailed advice on doseModerate Severe





• VI 13-15 mm TEA OR • Cystic PVL
• VI >97th percentile but < 4 mm
above 97th percentile for CGA
• Subcortical leucomalacia
• VI at TEA >15 mm OR
• VI >4 mm above 97th percentile
for CGA
• Basal ganglia (BG) lesions
• Focal infarction
• Multi-focal lesions in BG with
equivocal or abnormal signal
intensity within PLIC
• Widespread abnormalities involving
all Basal ganglia-Thalamus (BGT)
structures and PLIC
• Small focal lesions of
without loss of grey matter
(GM)/WM differentiation.
• Larger areas of abnormality with
loss of GM/WM differentiation,
consistent with infarction
• Central grey matter
hyperechogenicity +/− more
extensive cortical and subcortical
hyperechogenicity
• Focal, non-territorial infarct • Territorial infarct
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will be provided by the trial dietician (KL). The active sup-
plement contains DHA (1% total fatty acids), arachidonic
acid (AA), choline, UMP, multivitamins, trace elements
and minerals. The placebo contains multivitamins, min-
erals and trace elements only. Supplement sachets are la-
belled X or Y and are available in 2g, 3g and 12g
quantities. The supplements are produced under strict
Good Manufacturing Practice (GMP) conditions and do-
nated by Nutricia®, Netherlands, and have been deodorised
to minimise smell and taste. Parents and assessors will be
blinded as to whether X or Y is the active supplement.
Study assessments
A detailed schedule of the study assessments is shown in
Table 2.
Treatment monitoring and growth outcomes
Head circumference, weight, length, height, mid-arm cir-
cumference and skinfold thickness (triceps, biceps, supra-
iliac and sub-scapular) will be measured 3 monthly [36].
Participant whole blood fatty acid levels will be mea-
sured by heel or finger-prick [37] at trial entry and at
the end of supplementation. In the neonatal trial mater-
nal whole blood fatty acid levels will be measured. Blood
fatty acid levels at baseline and trial end will be corre-
lated with neurodevelopmental outcome.
Developmental assessment
The BSID II [38] has been widely used to determine rates
of developmental disability or disordered development
[39,40], and as an outcome measure in RCTs [41,42]. The
BSIDIII [43] has superseded the BSID II and includesTable 2 Schedule of trial assessments
Procedure Frequency Details
Feed supplementation Daily Both groups will
a milk feed daily




Anthropometry Every 3 months Measurements w
every 3 months
MRI/MRS 0 and 3 months This scan will be
chemistry and ch
Visual Event Related Potential
and behavioural vision testing
Baseline, term, 6 m,




child will also be
perform
Bayley Assessment Baseline, 12 and
24 months
The child will be
moving (sitting,
Vineland Assessment 12 and 24 months During a semi-st
about their child
Fatty acid profile analysis Baseline and 24 months 0.05mls of blood
Maternal fatty acid profile analysis Baseline 0.05mls of bloodseparate composite scores for cognitive, language and
motor scales. The BSID III will be administered in the
child’s home by a trained administrator (MA or CMJ). As-
sessments will be video-recorded for verification of
scoring.
The Vineland Adaptive Behaviour Scales II (VABS-II)
[44] is a standardised parental interview, and will be ad-
ministered by MA or CMJ following Bayley assessment,
as a parent report measure of child development.
Functional vision assessment
Vision assessment will be performed by MA and CMJ
under the supervision of Professors O Braddick and J
Atkinson. Assessments will be conducted in vision
testing facilities in the Women’s Centre, Oxford Uni-
versity Hospitals NHS Trust, Oxford. Infants will sit
on the caregiver’s lap during testing. The Atkinson
Battery of Child Development for Examining Functional
Vision (ABCDEFV) [45] will be used to assess perceptual,
motor, spatial and cognitive skills, and published normative
data are available [45].
Core vision tests will include orthoptic assessment
(ocular movements, pupil response), refractive errors,
binocular optokinetic nystagmus (OKN), acuity (Teller
acuity cards), and attention at distance, visual fields (Sty-
car balls), defensive blink and fixation shift. Age-specific
tests to identify problems in perceptual, visuo-motor
and spatio-cognitive domains will be included.
Neurophysiological measures
Phase and orientation reversal visual event related
potentials (PR- and OR-VERP) During VERP recording
infants sit in a darkened room on their caregiver’s lap,receive a measured feed supplement (active or placebo) to add to
ill take place in person or by telephone every two weeks or as required
of the trial
ill be taken using calipers and anthropometer at baseline and then
to monitor growth.
performed at baseline and then three months later to assess brain
oline uptake.
the child will be positioned on the parents lap or in a chair to view a
oving black and white stripes were shown. For the test 3 adhesive
e placed on the head and connected to a computer by fine cables. The
observed for reactions to moving stimuli and given simple tasks to
asked to do a number of activities to see if their thinking, language, and
walking) skills are similar to children his or her own age.
ructured interview the parents will be given a questionnaire to fill in
’s personal and social skills.
will be taken using a finger prick test.
will be taken using a finger prick test.
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placed on the infants scalp, over the occiput, forehead,
and vertex. Electrodes are connected to a low voltage
pre-amplifier. Stimuli are oblique black and white
stripes. For phase reversal VERPs (PR-VERP) the stripe
orientation is unchanged but contrast reverses periodic-
ally. For orientation reversal VERPs (OR-VERP) stripe
orientation changes between 45 and 135 degrees. Both
PR- and OR-VERPs are measured at transient (2 rever-
sals/second) and steady state (4–8 reversals/second). 100
sweeps are recorded at each reversal rate.
Neuro-imaging In the neonatal (D1) trial, brain proton
magnetic resonance spectroscopy (1H-MRS) will be used
to assess brain choline uptake in cases versus controls,
at baseline and following 3 months of supplementation.
MR studies cannot be performed beyond this age with-
out sedation.
1H-MRS and MRI studies will be performed using a
Philips 1.5 T Achieva machine, with an 8-channel
SENSE adult head coil. 1H-MRS will be performed in
natural sleep following a milk feed. In neonates and in-
fants 1H-MRS will also be performed at the end of the
intervention if MRI under general anaesthetic is per-
formed for clinical reasons. Axial T1 and T2 weighted
images will be obtained. T2 weighted images will be
used to place two 1H-MRS slices, one at basal ganglia
level, the other through the cerebral hemispheres above
the lateral ventricles. 1H-MRS acquisitions will be per-
formed using a manufacturer standard two-dimensional
CSI technique. The volume of interest will be sized so
that suppression bands (REST slabs) lie well within the
inner table of the calvarium. After automated shimming
and water suppression steps, spectra will be acquired for
each of the 25 voxels of the 5 × 5 matrix within the sam-
pled volume at each level. 1H-MRS data will be analysed
using a Philips Extended Workspace with SpectroView
software, which generates spectra for each voxel, per-
forms metabolite peak fitting for choline, creatine, N-
acetyl aspartate (NAA) and lactate, and calculation of
corresponding metabolite ratios.
The infant (D2) trial participants will not undergo
MRI/MRS as part of the protocol.
Data collection, storage and record keeping
Each participant will be allocated a unique study number
at the time of randomisation and this will be used through-
out the study to identify all data relating to the participant.
All assessment data collected by the research nurse, clinical
research fellow or dietician will be entered on paper then
transferred to a data protection compliant drive in the re-
search team’s office. All data will be double entered
and data entry errors corrected. Data stored on the
database will be updated by the University’s InformationManagement Services Unit every night. All patient identifi-
able information will be kept on encrypted computers in a
secure office, with access limited to authorised members of
the research team. In accordance with the requirements of
the University of Oxford, all data will be archived in secure
archive facilities within the University until three years
after the last participant reaches the age of eighteen. After
this time all documentation will be destroyed and all data
deleted securely. The final dataset will initially be available
only to the study team. After the results of the trials have
been reported, anonymous trial data will be made publicly
available.Sample size calculation
No previous studies have supplemented children with
this combination of micronutrients. Power calculations
were performed for primary outcome measure BSID-III
score, assuming power of 80%, 5% significance level, use
of two-sided statistical tests throughout and equal allo-
cation to each arm. Recruitment of 60 participants to
each trial (30 to each arm within each trial), assuming
20% loss to follow-up, provided 80% power to detect a
12.5 point difference in BSID-III score assuming stand-
ard deviation (SD) of 15 points. Power calculations were
also performed for secondary outcome VERP latency. 30
infants per group provided 90% power to detect a la-
tency difference of 25 ms, assuming SD of 25 ms and
significance level of 5%.Statistical analysis
Data analysis will be undertaken by the study statistician
at CSM using appropriate statistical software.
Continuous variables at baseline will be presented
using means and standard deviations (unless not nor-
mally distributed, in which case medians and percentiles
will be used).
Categorical/binary variables at baseline will be pre-
sented using proportions and percentages.
The primary outcome (change in Bayley score from base-
line) will be analysed at 12 and 24 months using mixed ef-
fects linear regression to account for the repeated measures
over time. Baseline Bayley score will be entered as a covari-
ate in the model. The mixed effects model will include Bay-
ley score at 12 and 24 months as the response variable, time
point (12 or 24 months), treatment group and baseline Bay-
ley score as fixed effects and a patient specific random inter-
cept. An interaction between time and treatment group will
be fitted as a fixed effect to allow estimation of treatment ef-
fect at both time points. The minimisation (design) factors
will also be included as fixed effects. The primary outcome
is Bayley score at 24 months. Mean difference in cognitive
score between the 2 groups at 24 months will be presented
along with 95% CI and associated 2 sided p-value.
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ity, thus invalidating the linear regression model, the
first approach will be transformation. If the data cannot
be transformed to normality, a Mann–Whitney test will
be adopted. The difference in median change from base-
line will be presented alongside the 95% CI for the dif-
ference in medians. There will be no adjustment for
covariates if the data cannot be transformed to allow
parametric analyses. Primary analysis will be conducted
on the Intention To Treat population.
All analyses of continuous outcomes will follow the
same procedure as the primary outcome analysis. Ana-
lysis of proportions will use binomial regression. Odds
ratios will be presented.
If missing data are substantial, multiple imputation
will be used to assess the impact of missing data in a
sensitivity analysis.Withdrawal of participants
Parents will have the right to withdraw their child from
the study at any time, for any reason, and without giving
a reason. The Chief Investigator will also have the right
to withdraw participants from the study in the event of
adverse events, serious adverse events, suspected unex-
pected serious adverse reactions or protocol violations.
Where parents withdraw before randomisation, comple-
tion of baseline assessments and without starting supple-
mentation, they will be replaced. If a parent decides to
withdraw their child from the study every effort will be
made to report the reason for withdrawal as thoroughly
as possible. Parents will be informed, prior to consenting
into the study, that should they subsequently withdraw
all data collected prior to their withdrawal will be main-
tained and used for the purposes of the study.Management of the study, quality control and assurance
The study will be managed through the University of
Oxford’s Clinical Trials Research Group and the re-
search team of the Paediatric Gastroenterology and Nu-
trition Group in the Department of Paediatrics. Quality
control will be maintained through adherence to the
study protocols, standard operating procedures, research
governance and clinical trial regulations.
An independent Data Monitoring and Ethics Commit-
tee, consisting of a senior medical statistician and two
independent paediatric clinicians, will meet part-way
through the study to provide independent review. It's
purpose will be to safeguard the interests of trial partici-
pants, assess the safety and efficacy of the interventions,
and monitor the overall conduct of the clinical study.
The committee will be chaired by one of the independ-
ent clinicians and will have access to unblinded study
data.Plans to communicate study results
No publications containing results from this study have
been published or submitted to any journal. Results will be
submitted to peer-reviewed journals for publication when
all statistical analyses have been completed and the study
unblinded. This should be in the summer of 2015.
The research team will contact all the participants
when the results of the study are available. Results will
be sent to all participants who expressed interest in re-
ceiving them.
Ethics committee and regulatory approval
The study will be conducted in accordance with ethical
principles as listed in the Declaration of Helsinki. Ethics
approval was granted by Oxfordshire REC B for both tri-
als. Approval for the neonatal trial was granted on 08
May 2008, number 08/H0605/70. Approval for the infant
trial 12 January 2009, number 08/H0605/155. A total of
6 substantial amendments were submitted to the REC
and approved as follows:
1st amendment - 19 February 2009
2nd amendment - 21 July 2009
3rd amendment - 7 January 2010
4th amendment - 13 May 2010
5th amendment - 10 August 2010
6thamendment - 13 November 2012.
Discussion
This novel project will be the first to provide all three
phosphatide precursors (DHA, choline and UMP) to in-
fants at risk of neurodisability. There are very few interven-
tions that have been shown to improve the
neurodevelopmental outcome of babies and infants with
PBI. To date therapeutic hypothermia for term hypoxic en-
cephalopathy is the only therapy which improves mortality
and morbidity outcomes [46]. There is a clear need to
identify other treatments capable of reducing morbidity in
infants who sustain perinatal brain injury. If successful,
dietary supplementation with this combination of phos-
phatide precursors will ameliorate the level of disability ex-
perienced by these children and their families.
This study has several advantages over previous studies
examining the effects of DHA supplementation on infant
neurodevelopment. Firstly, it provides DHA at 1% total
fatty acids, mimicking maximal levels found during third
trimester transplacental fatty acid transfer [47] and human
breast milk [48]. With the exception of the DINO trial [35],
previous fatty acid supplementation studies have given
DHA at much lower doses, and have not provided the add-
itional substrates required for normal neural development.
However, the combination of DHA with choline and UMP
has been shown to have positive synergistic effects on brain
phosphatide levels, synaptic elements and dendritic spine
density compared to when these nutrients are given alone.
Andrew et al. BMC Pediatrics  (2015) 15:22 Page 9 of 11This study will be the first to provide high dose DHA in
combination with choline and UMP. Furthermore, in con-
trast with other studies, most of which had a short inter-
vention period, this study will supplement infants for
2 years, throughout the period of maximal brain growth
and synaptogenesis. This will be a longer period of supple-
mentation than any previous DHA intervention trial, thus
minimising the likelihood of type 2 errors resulting from an
insufficient supplementation period. A further study
strength will be the range of outcome measures being
employed, utilising behavioural, neurophysiological and
neuroimaging measures.
If this study demonstrates a neurodevelopmental advan-
tage to supplementation with phosphatide precursors, the
supplement could be provided as part of routine clinical
care for babies with PBI, or the supplement’s effectiveness
could be tested in a larger multi-centre trial.Study status
The study is in progress and will continue until the last in-
fant recruited completes their 2 year participation. This is
anticipated to be in March 2015. A period of statistical
analysis will follow and it is anticipated that this will be
completed in the summer of 2015.
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